DHR · Jun 5, 2026NYSEDHRStock Research

+4

WatchlistResearch report read

Interactive slide deck

DHR diligence lens

Danaher Vs Agilent: Which Life Science Giant Wins The Recurring Revenue War?

Danaher and Agilent both sell into durable lab workflows, but the winner depends on recurring mix, margin quality, and cash conversion.

ClaimFilingCashCustomerConviction

Slide mode Article mode

Danaher and Agilent both sell into durable lab workflows, but the winner depends on recurring mix, margin quality, and cash conversion.

References

Sources used in this report

SEC filingDHR latest SEC filing2026-04-21 · Latest official filing baseline, risk context, and financial statement evidence.SEC XBRL companyfactsDHR SEC companyfacts2026-06-05 · Revenue, cash, net income, operating cash flow, assets, liabilities, and R&D facts where tagged.Comparator official filing baselineA latest SEC filing and companyfacts2026-06-01 · Comparator baseline for the requested DHR versus A analysis.